These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32796479)

  • 21. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL.
    Garza D; Kandathil A; Xi Y; Subramaniam RM
    Nucl Med Commun; 2021 Aug; 42(8):907-913. PubMed ID: 33741863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.
    Chen B; Macapinlac HA; Lu Y
    Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bicentric retrospective analysis of clinical utility of
    Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
    Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
    J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [
    Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
    J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSMA-targeted Radiotracers versus
    Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
    Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of 18F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy.
    Payne H; Bomanji J; Bottomley D; Scarsbrook AF; Teoh EJ;
    Nucl Med Commun; 2022 Feb; 43(2):201-211. PubMed ID: 34669678
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Eiber M; Kroenke M; Wurzer A; Ulbrich L; Jooß L; Maurer T; Horn T; Schiller K; Langbein T; Buschner G; Wester HJ; Weber W
    J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
    [No Abstract]   [Full Text] [Related]  

  • 38.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic performance of
    Teyateeti A; Teyateeti A; Ravizzini GC; Xu G; Tang C; Tu SM; Macapinlac HA; Lu Y
    Am J Nucl Med Mol Imaging; 2021; 11(2):87-98. PubMed ID: 34079638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.